NeuroMetrix Return On Tangible Equity 2010-2024 | NURO

NeuroMetrix return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

NeuroMetrix Return On Tangible Equity 2010-2024 | NURO

NeuroMetrix return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$195.6B
Stryker (SYK)$137.3B
Boston Scientific (BSX)$122.7B
Medtronic (MDT)$114.6B
EssilorLuxottica (ESLOY)$108.8B
Haleon (HLN)$48.7B
Lonza Group Ag (LZAGY)$46B
ResMed (RMD)$35.1B
Koninklijke Philips (PHG)$30.8B
Terumo (TRUMY)$28.5B
Zimmer Biomet Holdings (ZBH)$22B
Baxter (BAX)$19.9B
Insulet (PODD)$16.3B
Smith & Nephew SNATS (SNN)$13.6B
Bio-Rad Laboratories (BIO)$9.2B
Demant (WILYY)$8.7B
BellRing Brands (BRBR)$7.9B
Lantheus Holdings (LNTH)$7.5B
ICU Medical (ICUI)$4.3B
Haemonetics (HAE)$4.1B
TG Therapeutics (TGTX)$3.7B
Neogen (NEOG)$3.6B
Prestige Consumer Healthcare (PBH)$3.5B
GN Store Nord (GNNDY)$3.5B
Perrigo (PRGO)$3.5B
Envista Holdings (NVST)$3.4B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Green Thumb Industries (GTBIF)$2.2B
Maravai LifeSciences Holdings (MRVI)$2.1B